|
|
Press Releases [2010]
THOMSON REUTERS ACQUIRES GENEGO: RESULTING SOLUTIONS WILL HELP BIOPHARMA AND ACADEMIC RESEARCHERS DESIGN BETTER DRUGS
Philadelphia, PA, London, UK, November 29, 2010 — Thomson Reuters today announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development.
Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters. Financial terms of the transaction were not disclosed.
The acquisition enables Thomson Reuters to provide the pharmaceutical, biotechnology, and academic research communities with solutions that provide better understanding of the underlying mechanism of disease and potential therapies. GeneGo’s scientific expertise and assets in biology-driven drug discovery complement the Thomson Reuters life sciences portfolio that covers drug pipeline competitive intelligence, patents, and chemistry.
“Thomson Reuters now provides comprehensive decision support solutions to help researchers striving to bring more effective medications to market,” said Jon Brett-Harris, executive vice president at Thomson Reuters. “There is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalized approach to medicine.”
GeneGo’s capabilities include:
- MetaBase™, a comprehensive and respected knowledge base in systems biology.
- Expertise in analytics, data management, and value-added services.
- An experienced management team and a skilled scientific staff.
- A successful track record deploying decision support systems.
GeneGo is headquartered in San Diego and has offices in Moscow and Michigan.
Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
GENEGO ANNOUNCES INTEGRATION WITH AGILENT’S GENESPRING BIOINFORMATICS SOLUTION
St Joseph, Michigan, November 22nd, 2010 - GeneGo Inc., a leading provider of databases, software and services in systems biology and chemistry, and Agilent Technologies, Inc., the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications announced today that they have integrated Agilent’s Genespring Bioinformatics Solution with MetaCore.
GeneSpring GX 11.5, released today, introduces a multi-omics microarray and mass-spectrometry based analysis suite to handle transcriptomics, genomics, metabolomics and proteomics data in one application. GeneSpring GX 11.5 includes a direct connection to the MetaCore pathway analysis engine that allows users to seamlessly upload expression data analyzed in GeneSpring for pathway analysis in MetaCore. This connection is part of every expression workflow in GeneSpring, allowing automatic experiment creation and entity annotation in MetaCore.
“We are very pleased to integrate GeneGo’s MetaCore pathway analysis capabilities into GeneSpring’s expression workflows”, said Michael Janis, GeneSpring Product Manager at Agilent Technologies. “Our users have access to industry-leading analysis and visualization tools within GeneSpring and the ability to combine statistical analysis in GeneSpring with MetaCore’s strengths in pathway analysis will enable a deeper understanding of their research in a biological context”.
“This will allow our joint customers to seamlessly work with omics data in the context of pathways”, said Julie Bryant VP of business development. “MetaCore can concurrently visualize multiple types of data and will be able to take advantage of this new functionality in GeneSpring which will be very helpful to our joint customers.”
GENEGO ANNOUNCES INTEGRATION WITH GENOMEQUEST FOR PATHWAY ANALYSIS OF NEXT GENERATION SEQUENCING DATA
St Joseph, Michigan, October 7th, 2010 - GeneGo, Inc., a leading provider of
databases, software and services in systems biology and chemistry, announced today that
they have integrated GenomeQuest’s Sequence Data Management (SDM) platform with
GeneGo’s MetaCore and MetaDrug.
Using GenomeQuest’s interactive analysis, scientists who have drilled down to a list of
particular genes of interest (hundreds of millions of reads, to thousands of expressed
genes, to dozens or more of particular genes of interest) can now seamlessly pass that
gene list along with their associated expression values (RPKM) to the GeneGo suite of
pathway analysis software tools.
“The ability to analyze hundreds of datasets, reducing millions of reads down to a shorter
list of particular genes of interest, and then being able to visualize where those genes are
active in specific (potentially disease-related) pathways, is a significant accomplishment
in the integration of omics software offerings. Scientists will be able to quickly focus on
their scientific questions, rather than manipulating large reads datasets and lists of
thousands of genes. We believe this will enhance discovery throughout the genomics and
proteomics research pipelines,” said Dr. Don Gregory, GenomeQuest’s Director of Field
Application Scientists.
“This integration will allow our joint customers to seamlessly work with NGS data in the
context of pathways”, said Julie Bryant VP of business development for GeneGo. “The
integrated workflows will lead our users from raw sequence runs to functional hypothesis
generation of drug targets and biomarkers. With NGS data picking up steam in
translational medicine and individual healthcare, this integration will help us to leverage
our unique disease pathology maps (causal models) developed in our MetaMiner
programs in oncology, CNS, metabolic, respiratory diseases and other therapeutic areas.”
GENEGO AND OMICSOFT COLLABORATE ON PATHWAY ANALYSIS FOR NEXT GENERATION SEQUENCE DATA
St. Joseph, MI. September 29th, 2010 –GeneGo, Inc., the leading systems biology tools
company and Omicsoft Corporation, the leader in the OMIC repository and analysis
field, announced today integration of Omicsoft‘s Next Generation Sequencing tools with
GeneGo‘s MetaCore data mining suite.
Array Studio, Omicsoft‘s software package that provides state of the art statistics analysis
and visualization tools for high dimensional quantification data (OMICS data), also
supports analysis of Next Generation Sequencing Data (both RNA-Seq and DNA-Seq).
Omicsoft has developed high performance proprietary sequence alignment algorithms for
the major NGS platforms, i.e. Illumina’s Solexa, Roche’s 454 and SOLID from Life
Technologies. Array Studio fully supports known and novel exon junction detection,
fusion gene detection (both single end and paired end), expression value calculation,
along with mutation reporting/annotation and more, all in one easy-to-use software
package which provide complete analysis from machine-generated sequence runs to the
lists of modified genes and polymorphisms.
Array Studio is seamlessly integrated with GeneGo‘s data mining suites MetaCore and
MetaDrug, allowing in depth analysis of the users NGS data.
“Omicsoft is delighted to continue its partnership with GeneGo, as the –OMICs field
enters a new era with next generation sequencing technology. We feel that our alignment
algorithm, coupled with our industry leading visualization and statistical package Array
Studio, will allow us to continue to pave the way in the –OMICs industry. The extra
benefits provided by NGS platforms, for instance, detection of gene fusion, will play a
key role in biomarker discovery in cancer genomics. Integration with GeneGo’s
platforms is key to this success, through their tools for systems biology,” said Jack Liu,
President of Omicsoft.
“We are happy to extend our long-term collaboration with Omicsoft into next-generation
sequencing”, said Julie Bryant. GeneGo’s VP of Business development. “NGS
technologies provide the richest content data in life sciences, and we believe that they
have one of the most comprehensive solutions. Pathway and network analysis is a natural
next step for these complex data, and we are glad that we can provide our customers with
a seamlessly integrated workflows from raw sequence data to biologically meaningful
hypotheses on biomarkers, drug targets and drug repositioning.”
GENEGO AWARDED NIDA GRANT TO DEVELOP PLATFORM FOR RESEARCH ON NICOTINE ADDICTION
St. Joseph, MI. September 21st, 2010 – GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant from the National Institute on Drug Abuse to develop an integrated systems biology platform for research into the causes and treatment of tobacco dependence, nicotine addiction, smoking cessation and tobacco/nicotine withdrawal. The SBIR grant will be used to develop a database and systems biology tool-set specifically designed for the study of the pathways involved in nicotine addiction and withdrawal, mutations and sequence heterogeneity in human genes and their controlling regions that affect these responses, and the evaluation of new targets, therapeutic strategies, and biomarkers for treatment of nicotine addiction.
“One in five adults in the US smokes according the CDC, and it is estimated that smoking kills 1,000 Americans per day.” Said Richard Brennan, Director of Toxicology at GeneGo and PI on the grant. “A holistic understanding of the complex biological pathways involved in the pharmacological and addictive effects of nicotine is needed to better understand and treat the causes of addiction and symptoms of withdrawal to help those who want to quit be successful. This project will gather existing knowledge and data to reconstruct these pathways and make them accessible to researchers and clinicians working in a variety of areas related to this persistent problem via MetaCore.”
“We are delighted to receive this grant.” said Julie Bryant, GeneGo’s VP of Business development. “The NIDA has recognized the strength of GeneGo’s scientific expertise and our capabilities in providing new and critical systems biology tools for disease research. Similar previous projects in Cystic Fibrosis and other diseases are already helping to deliver new drugs and treatment strategies to clinicians, and we hope that this project will do the same to help understand nicotine addiction.”
UNIVERSITY OF LUEBECK JOINS GENEGO’S METAMINER CARDIAC PROJECT
St Joseph, Michigan, July 20th, 2010 - GeneGo, Inc., a leading provider of databases,
software and services in systems biology and chemistry, announced today that Dr. Salah Mohamed in Department of Cardio and Thoracic Vascular Surgery at the University of Luebeck and his team will be part of the Metaminer Cardiac Partnership. Dr. Mohamed is published within 6 different reputed Scientific American Journals in connection with Biomarker Discovery work performed for the American Heart Association.
Mohamed and colleagues theorized that the cause of acute aortic dissection lay in the interaction of other proteins with the protein MS FBN1. That protein is encoded by a mutated gene linked to Marfan syndrome. Researchers found 88 genes in the tissue of all 19 acute aortic dissection patients who had gene expression — the process that converts a gene’s encoded information into a protein —significantly different from the same genes in the Marfan patients and the control group. Further investigation revealed that the MS FBN1 protein interacted directly with the proteins of four of the 88 genes — fibulin 1 (FBLN1), fibulin 2 (FBLN2), Decorin (DCN) and microfibrillar associated protein 5 (MFAPS5).
“Interestingly, one of these four proteins is considered as a candidate in the development of Marfan syndrome,” Mohamed said. “The study was also aimed at the future development of a clinical test for monitoring patients with a high risk of acute aortic dissection. Most acute aortic dissection patients do not have a known connective tissue disorder. The identification of the four genes could be a starting point to develop a diagnostic tool, and we plan to utilize GeneGo’s tools to further this study.”
“Dr. Mohamed and his group are going to bring a lot of domain knowledge to the MetaMiner Cardiac Project which is essential to its success,” said Julie Bryant, VP Business Development of GeneGo. “Cardiac disease reconstruction pathway maps are unique to GeneGo and we have been pioneers in this field. We are also looking for more Pharmaceutical members with domain expertise.”
GENEGO’S TOXHUNTER SUITE OF TOOLS AND CONTENT FOR SYSTEMS TOXICOLOGY RESEARCH IS NOW AVAILABLE
St. Joseph, Michigan, July 13th, 2010 – GeneGo announced the availability of ToxHunter™, the first commercial release of tools and content developed through its industry-FDA MetaTox™ partnership program, a collaborative program developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D.
ToxHunter is now available as an add-on to existing licenses of GeneGo’s MetaCore™ and/or MetaDrug™ systems biology and systems pharmacology platforms.
ToxHunter includes a unique, detailed ontology of compound-induced pathological observations covering 8 target organs in the initial release. This ontology is populated with a comprehensive, manually-curated knowledgebase of toxicant associations to pathology terms along with gene, protein, metabolite biomarkers of chemical toxicity. Content is searchable by pathology, toxicant, or gene, protein & metabolite biomarkers. ToxHunter enables new experimental analysis and visualization tools such as an exclusive enrichment module for identifying specific gene-pathology associations, a suite of new toxicity-focused pathway maps and QSAR models, and the ability to overlay toxicity biomarker information on maps and interaction networks.
“We are excited to provide this unique and powerful set of tools to better support our customers in safety assessment, who are making increased use of existing knowledge in concert with their own molecular data, in a systems approach to understand and predict adverse outcomes of chemical exposure.” said Richard Brennan, Director Toxicology. “We will expand the capabilities of the platform in regular future updates, as more of the tools developed by the partnership are released.”
“Our toxicology customers recognize the value of ToxHunter to their research.” said Julie Bryant, VP Business Development. “The enthusiastic responses to demonstrations of pre-release versions, and strong pre-release sales to government, academic, clinical, and commercial customers validate the partnership program’s ability to deliver tools and content with value in the marketplace.” Numerous organizations, including Merck-Serono, The Hamner Institutes for Health Sciences, and the National Toxicology Program of the NIEHS have already licensed ToxHunter under GeneGo’s pre-sale program.
GENEGO IS AWARDED NCI PHASE II GRANT FOR DEVELOPMENT OF A PLATFORM FOR INTEGRATIVE DATA ANALYSIS IN CANCER
St. Joseph, Michigan, June 22nd, 2010 - GeneGo Inc., a leading provider of databases,
software and services in systems biology and chemistry, announced today that they were awarded with a Phase II SBIR grant from the National Cancer Institute (NCI) for further development of an analytical platform for translational research and data analysis in oncology. NCI funding will support the industry and academia collaborative project MetaMiner (Oncology) run by GeneGo with investigators at Harvard Medical School, Johns Hopkins University, Tgen, Van Andel Institute and several global pharmaceutical companies. The MetaMiner platform combines disease reconstruction of multiple cancers, OMICs data repository and advanced statistical tools based on pathway descriptors.
“We are very pleased with NCI’s decision to continue support for our MetaMiner(Oncology) platform, which is tailored for biologists, bench scientists, clinicians and medicinal chemists working in oncology,” said Yuri Nikolsky, CEO of GeneGo and the grant’s PI. “Over the last two years, we have created a general framework for disease reconstruction (causal disease models) and annotated many thousands of ‘causative’ links between genes, perturbed pathways and seven different cancers. We see target discovery, translational cancer research and personalized diagnostics as the top application areas for MetaMiner (Oncology).”
“There are many ‘generic’ pathway tools on the market, helpful to some extent in cancer data analysis. However, none of them is centered around cancer biology, which is essential,” says Kornelia Polyak, an Associate Professor at Dana-Farber Cancer Institute and a consultant on the grant. “Another focus is on the development of pathway-based tools for integration of different types of OMICs data – somatic mutations, high copy number genes, epigenetics, gene expression, proteomics and metabolomics.”
THE INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (CTSI) LICENSES GENEGO’S EUREKA AND METACORE PLATFORMS
St. Joseph, Michigan, March 23rd, 2010 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the Indiana Clinical and Translational Sciences Institute (CTSI) has licensed its pathway analysis suite MetaCore and its database searching tool Eureka. The CTSI is based on a $25 million National Institutes of Health Clinical and Translational Science Award (CTSA) and is a partnership between Indiana University, Purdue University, and the University of Notre Dame. GeneGo will embed its Eureka platform into the CTSI website for use by all CTSI researchers.
The CTSI portal, called the Indiana CTSI HUB (http://www.indianactsi.org/), is a content management system that is designed to be the central clearinghouse for translational research activities for health care researchers at the IU School of Medicine and ultimately across the state of Indiana. The goals of the CTSI are to create research acceleration programs and support pilot projects, train a new cadre of translational researchers, foster robust community engagement, build facile and comprehensive resources and technologies, and leverage the resources of the greater Indiana community.
“A primary goal of the Indiana CTSI Translational Technologies Program (TTR) is to build an infrastructure that enhances the opportunity for our researchers to utilize state-of-the-art technologies. GeneGo’s agreement to provide access to their software tools to all investigators across our partner institutions at a cost equivalent to that for a few researchers to purchase their own agreements significantly contributes to this goal and offers an expanded opportunity for inter-campus collaborations,” said Lilith Reeves, Chief Scientific Officer, Indiana CTSI, IUSM. The partner institutions include the Indiana University School of Medicine, Purdue University, University of Notre Dame, Indiana University Bloomington, and Indiana University-Purdue University Indianapolis.
“Eureka is an easy to use “Google-like” interface that allows researchers to leverage the excellent quality of GeneGo’s database in their everyday workflows,” said Julie Bryant, VP of Sales and Business Development at GeneGo. “Indiana is on the cutting edge of translational research with its excellent universities and we are pleased to be a part of this.”
GENEGO RELEASES CONTENT AND TOOLS FROM INDUSTRY-FDA DRIVEN METATOX PARTNERSHIP VIA TOXHUNTER
GeneGo announces the release of the first set of tools and content to come out of its industry-FDA MetaTox™ partnership program. The MetaTox partnership is developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D.
ToxHunter will be made available as an add-on to existing licenses of GeneGo’s MetaCore™ and/or MetaDrug™ systems biology and systems pharmacology platforms.
ToxHunter includes a unique, detailed ontology of compound-induced pathological observations covering 7 target organs in the initial release, as well as a comprehensive, manually-curated knowledgebase of gene, protein, metabolite, and chemical associations to pathology terms that is searchable by pathology, toxicant, or gene, protein & metabolite biomarkers. ToxHunter also enables new experimental analysis and visualization tools such as an exclusive enrichment module for identifying specific gene-pathology associations, and a suite of new toxicity-focused pathway maps and QSAR models.
“It is immensely exciting to see the ideas and input of the MetaTox partnership come to fruition through the hard-work and dedication of the GeneGo team,” said Richard Brennan, Director of Toxicology at GeneGo. “This initial release provides the community with a unique and powerful set of tools to help make sense of the flood of molecular data being generated by modern safety assessment groups. The next 12-18 months will see a further expansion of the capability of the platform as more of the tools developed by the partnership are released.”
“It is very important to GeneGo and our end users that we build these tools and content in collaboration with partners as they know exactly what they need and what is currently missing in the marketplace,” said Julie Bryant, VP Business Development. “We truly believe we have delivered important productivity tools to the tox field based on the extremely positive feedback we have already received from ToxHunter demonstrations.”
GeneGo will be demonstrating ToxHunter at the annual meeting of the Society of Toxicology in Salt Lake City, Utah, this week (booth #1937, March 7-11), and is offering a 50% discount on the full price to anyone who licenses this new ToxHunter prior to release (offer good through June 30th, 2010 with a signed purchase agreement and payment).
THE UNIVERSITY OF AMSTERDAM JOINS THE METAMINER METABOLIC DISEASES PROJECT
St. Joseph, MI. February 22nd, 2010 – GeneGo, Inc., the leading systems biology tools company, announced today that the Medical Biochemistry group at the Academic Medical Center, University of Amsterdam will join the MetaMiner Metabolic Diseases project from GeneGo. The MetaMiner program is focused on the fundamental understanding of human diseases at the level of disease pathways and causative gene-disease associations supported by a repository of OMICs data. Ongoing MetaMiner projects include Oncology, CNS, Cystic fibrosis and Stem cells.
“GeneGo provides unique, innovative reconstructions of disease pathways that are fundamentally important and required for the understanding of disease processes so we can find cures,” said Milka Sokolovic, PhD, Medical Biochemistry, Academic Medical Center, Amsterdam. “We want to be a part of this innovation to have access to high quality resources to build pathways we need for our research programs that we will use to publish.”
“The University of Amsterdam group is well known for their research on nutrition and fasting and we really welcome Milka’s expertise in this area,” said Julie Bryant, GeneGo’s VP of Business Development. “This will be the first ‘systems analysis’ platform devoted specifically for metabolic diseases. We will start with the ‘usual suspects’ of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism.”
UNIVERSITY OF MARYLAND SCHOOL OF NURSING LICENSES GENEGO’S METACORE PLATFORM
St. Joseph, Michigan, January 19th, 2010 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the University of Maryland School of Nursing has licensed its pathway analysis and knowledge mining suite MetaCore. The latest version, MetaCore 6.0 includes a new easy to use interface, with unique interactome analysis tools, simple searching of GeneGo’s high quality manually curated content and direct links from the drug detail pages to Sigma Aldrich for purchasing compounds.
“We prefer the coverage and quality of disease annotation, as well as the rodent specific pathway analysis, which is critical to seeing species differences. I am not aware of another platform that has this capability,” said Susan Dorsey, Director, UMB Center for Pain Studies.
“We are always told that we have the broadest and deepest coverage of content in the systems biology pathway area with the highest quality manual curation,” said Julie Bryant, VP of Business Development. “As we focus on building our disease platforms our depth of coverage will continue to grow and provide more levels of granularity for our users on diseases, processes and toxicology.”
GENEGO RECEIVES SBIR GRANT
St. Joseph, MI. January 12th, 2010 – GeneGo, Inc., the leading systems biology tools company, announced today they have been awarded $336K Phase I SBIR grant from the NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES for creating a novel type of predictive signatures for drug resistance. Under this project GeneGo will develop “regulation signatures” which should overcome many shortcomings of existing methods of molecular diagnostics. For this work GeneGo will utilize its extensive, manually-curated database of signaling interactions and recently developed algorithms for identifying key proteins in signaling networks. The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.
“What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels. We are very excited about the opportunity provided by NIH support to further develop and validate this approach. If successful, the methodology could be replicated for developing predictive models for sensitivity to a broad range of targeted therapies, leading to a number of diagnostic applications such as specialized molecular tests, systems for formulating combination therapies and procedures for selecting patient cohorts for clinical trials” said Andrej Bugrim, GeneGo COO and PI on the grant.
GENEGO LAUNCHES EASY ACCESS TO SIGMA ALDRICH PRODUCTS FROM METACORE, METADRUG AND EUREKA!
St. Joseph, MI. January 7th, 2010 –GeneGo, Inc., the leading systems biology tools company, announced today that they have launched easy access to many Sigma Aldrich life science and chemistry products from their “Drug Details” pages in three products: MetaCore 6.0, MetaDrug and Eureka! This new capability allows customers to retrieve comprehensive information on drugs and compounds and make one-click purchases all from one centralized location. Such efficiency tools are crucial to busy bench scientists.
“It’s critical that Sigma Aldrich has a presence through out all stages of an experiment’s life cycle,” said Nathan Allen, Market Segment Manager, Sigma Aldrich. “By incorporating our products into MetaCore, MetaDrug, and Eureka! we ensure that researchers have easy access to Sigma Aldrich products presented in the appropriate context during the initial stages of experiment preparation.”
“We have many mutual customers requesting easy access to product vendors such as Sigma Aldrich, so it was the logical thing to do,” said Julie Bryant, GeneGo’s VP of Business development. “In a typical workflow, our users formulate hypotheses, for instance on a mode of action for a new drug, followed by a set of validation experiments. The new tool allows them to find the necessary compounds for the experiments, cost out a project and make purchases on the relevant Sigma Aldrich landing pages.”
GENEGO TO SELL OMICSOFT PRODUCTS
St. Joseph, MI. January 5th, 2010 – GeneGo, Inc., the leading systems biology tools company, announced today that they will be selling Omicsoft products Array Studio and Array Server globally except for Japan. Array Studio is a software package which provides state of the art statistics and visualization for the analysis of high dimensional quantification data (OMICs data). Array Server is an enterprise data repository solution, allowing users to store, share, search, and integrate their microarray/SNP/CNV projects and data. These tools are seamlessly integrated with GeneGo’s data mining suites MetaCore™ and MetaDrug™ allowing in depth analysis of different types of OMICs data.
“We are very delighted to set up this collaboration with GeneGo Inc. At Omicsoft, we focus on biomarker data management, visualization, and analysis. To achieve this, we design software that is easy enough to be used by the bench scientist, but powerful enough to be used by the bioinformatician or statistician. We have also fully analyzed more than 5,000 public datasets for our users. Interpretation of both public and proprietary datasets requires sophisticated bioinformatics tools such as those from GeneGo. GeneGo’s success in this area is unparalleled, and we hope to contribute to their continued success with this agreement. The collaboration was triggered by the same feature-on-demand philosophy shared by the two companies: improving our solutions based on customer requests. With this partnership, Omicsoft can continue to focus on new technology developments, including next generation sequencing enterprise solutions.”, said Jack Liu, President of Omicsoft. “Interpretation of complex OMICs datasets requires both empirical statistical analysis of large data repositories and “knowledge-based” functional analysis based on manually curated pathways and ontologies. We believe that Omicsoft’s and our products are “best in class” in the corresponding fields, so bundling our solutions makes perfect scientific and commercial sense”, said Julie Bryant, GeneGo’s VP of Business development. “Many of our customers see the value in easy access, search and retrieval of public domain experimental data, followed by functional “pathway” analysis, including ontology enrichment, networks and interactome topology. While working with Omicsoft, we were impressed with their tools and now we look forward to representing them in the field.”
|
